Clinical Study

Prophylactic Administration of Surfactant in Extremely Premature Infants

Lutz Koch, David Frommhold, Bernd Beedgen, Peter Ruef, and Johannes Poeschl

Division of Neonatology, Department of Pediatrics, University of Heidelberg Medical School, Im Neuenheimer Feld 430, 69120 Heidelberg, Germany

Correspondence should be addressed to Lutz Koch, lutz.koch@med.uni-heidelberg.de

Received 26 August 2009; Revised 21 January 2010; Accepted 24 March 2010

Academic Editor: Ira Cheifetz

Copyright © 2010 Lutz Koch et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Objective. To investigate whether prophylactic surfactant administration is superior over selective treatment in preterm infants with respiratory distress syndrome (RDS). **Methods.** In our retrospective analysis, we compared premature infants (23 + 0 to 26 + 6 weeks) receiving 200 mg/kg surfactant (curosurf®) within five minutes after birth (prophylactic group, $N = 31$) with those infants who received surfactant therapy for established RDS (selective group, $N = 34$). **Results.** Prophylactic therapy significantly decreased the need for mechanical ventilation (74 hours per patient versus 171 hours per patient, resp.). We observed a reduced incidence of interstitial emphysema (0% versus 9%, resp.), pneumothoraces (3% versus 9%, resp.), chronic lung disease (26% versus 38%, resp.), and surfactant doses per patient (1.3 versus 1.8, resp.), although those variables did not reach significance. **Conclusion.** We conclude that infants under 27 weeks' gestation profit from prophylactic surfactant administration by reducing the time of mechanical ventilation. This in turn could contribute to reduce the risk for mechanical ventilation associated complications, without any detrimental short-term side effects.

1. Introduction

Evidence from randomized, controlled trials, as summarized in the Cochrane systematic reviews, demonstrates that prophylactic surfactant administration to infants judged to be “at risk” for developing respiratory distress syndrome, compared to selective use of surfactant in infants with established RDS, improved outcomes for high-risk preterm infants [1]. The use of surfactant for the treatment or prophylaxis of neonatal RDS results in a 30–65% relative reduction in the risk of pneumothorax and up to a 40% relative reduction in the risk of mortality. Adverse events are infrequent, and long-term follow-up studies are reassuring. Prophylactic administration of surfactant may be preferable to rescue treatment, especially in infants <30 weeks of gestation, as it decreases the risk of pneumothorax, pulmonary interstitial emphysema, and neonatal mortality [2], but may result in some babies being intubated and receiving therapy unnecessarily. These trials were carried out in the early 1990s when prenatal steroids were used less than currently and the respiratory assistance with noninvasive

nasal continuous positive airway pressure (CPAP) was poorly adopted in very preterm infants. Nasal CPAP is currently a first-line technique of respiratory support in newborns, and its use as an alternative to intubation and mechanical ventilation, also in extremely low gestational age infants, is well documented [3, 4], but no clinical trial compared initial CPAP and rescue surfactant therapy with initial intubation and prophylactic surfactant administration. Therefore, it remains unclear which criteria should be used to select “at risk” infants who would require prophylactic surfactant administration.

In our retrospective analysis, we based our comparison of prophylactic with selective surfactant treatment on the hypothesis that infants under 27 weeks' gestation are “at risk” in developing RDS and may profit from prophylactic surfactant administration.

2. Methods

Preterm infants with a gestational age between 23 + 0 and 26 + 6 weeks + days born in our center during the observation

period from January 2007 to December 2007 were eligible for the study.

Infants included in the study received $200 \text{ mg} \cdot \text{kg}^{-1}$ of a natural surfactant preparation (curosurf®, Chiesi, Germany) via intratracheal tube within five minutes after birth. The outcome criteria were compared with a historical control group of patients treated in the 12 months immediately before the observational period. These control infants were treated with CPAP at 5-6 cm H₂O and were intubated and received surfactant therapy only for established RDS ($\text{FiO}_2 > 0.4$ to maintain SpO_2 between 85% and 93%). Infants who needed tracheal intubation and mechanical ventilation for primary resuscitation received surfactant within 20 minutes after birth. In both study groups, infants were extubated as soon as $\text{FiO}_2 < 0.3$ and a mean airway pressure $< 7 \text{ cm H}_2\text{O}$ was reached. Immediately after extubation, CPAP at 5-6 cm H₂O was started using a stephanie respirator. CPAP was discontinued when the neonate remained stable with PCO_2 , oxygen saturation, and no CPAP for more than four consecutive hours. No other changes in intensive care management occurred during the study period.

Outcome criteria such as chronic lung disease (CLD), defined as the need of additional oxygen after 36 weeks gestational age, intraventricular hemorrhage (IVH) $> \text{II}$ according to the classification of Papile, periventricular leukomalacia (PVL), pulmonary interstitial emphysema (PIE), patent ductus arteriosus (PDA), rate of nosocomial infection, usage of postnatal steroids (hydrocortisone), and necrotizing enterocolitis (NEC) stadium II or III according to Bell are also reported.

Echocardiographic criteria for treatment of PDA included an increased left atrial diameter compared with aortic root (ratio > 1.2), visualization of the ductus ($> 2 \text{ mm}$), and evidence of left-to-right blood flow through the open duct as summarized by Sperandio et al. [5]. Nosocomial infection was defined according to NEO-KISS criteria. It is based on the US Centers for Disease Control and Prevention (CDC) criteria and has been adapted for this specific age group [6].

Postnatal steroid therapy with hydrocortisone was started when the postnatal age was > 1 week and the children was ventilator-dependent with increasing oxygen requirements or needed oxygen $> 40\%$ on CPAP or oxygen cannula. Infants received hydrocortisone according to a well established nine-day protocol: 3 days $45 \text{ mg/m}^2/\text{d}$ ($\sim 4\text{-}5 \text{ mg/kg}$), tapered to $30 \text{ mg/m}^2/\text{d}$ ($\sim 3 \text{ mg/kg}$) for another 3 days followed by $15 \text{ mg/m}^2/\text{d}$ ($\sim 1\text{-}2 \text{ mg/kg}$) for 3 days, given 3 times a day according to the circadian rhythm.

The study was carried out in accordance with ethical guidelines for human studies.

3. Statistics

Data are given as mean and range or number (percentage) and were analyzed with SPSS software (SPSS for Mac, version 16.0, Chicago, IL). The baseline characteristics of the two groups were compared using Student's *t*-test for parametric and the chi-squared test for nonparametric comparisons. *P*-values $< .05$ were considered statistically significant.

4. Results

Thirty-one infants with a gestational age between $23 + 0$ and $26 + 6$ weeks + days were born and treated in our center during the observational period of 12 months. There were no significant differences between birthweight, gestational age, sex, use of antenatal steroids, APGAR-score, rate of SGA (small for gestational age, birth weights below 10th percentile), and rate of multiple births of all patients treated in the observational period and historical control period as Table 1 shows. In each group, one patient suffered from serious hydrops fetalis. Twin to twin transfusion appeared in one twin birth in each group. Furthermore, in the selective surfactant group one patient had unknown trisomy 18.

Table 2 shows the mortality and morbidity rates for all patients of the prophylactic and selective surfactant group. Prophylactic surfactant therapy was associated with improved respiratory outcome. The duration of mechanical ventilation was tremendously and significantly shorter in the prophylactic surfactant group compared to the selective surfactant group (74 hours per patient versus 171 hours per patient, resp.). In addition, we found a reduced incidence of PIE (0% versus 9%, resp.), pneumothoraces (3% versus 9%, resp.), and CLD (26% versus 38%, resp.), although those variables did not reach significance.

There were no differences between diagnosis (71% versus 82%, resp.) and treatment (68% versus 68%, resp.) of PDA and nosocomial infections (45% versus 44%, resp.). The incidence of NEC stadium II or III according to Bell was increased in the selective surfactant group (3% versus 15%, resp.), although this variable did not reach significance.

The use of postnatal steroids was not different in both groups (61% versus 62%, resp.). Interestingly, we found a decreased number of surfactant doses used per patient in the prophylactic group (1.3 versus 1.8, resp.).

5. Discussion

Recent randomized and controlled trials demonstrated that prophylactic or early surfactant as compared to delayed rescue surfactant treatment results in improved outcomes for high-risk preterm infants [1, 7, 8]. However, the trials did not provide a definitive answer to the question of best timing of surfactant application at different gestational ages. Moreover, these data have been obtained in the early 1990s when prenatal steroids were used less than currently and the respiratory assistance with noninvasive nasal CPAP was poorly adopted in very preterm infants. Despite the advantages of prophylactic surfactant strategy for infants born less than 30 weeks' gestation, many such infants treated only after RDS has become established. In a large North American cohort of 47608 infants less than 30 weeks of gestation born between 1998 and 2000, only 27% received surfactant in the delivery room and 44% received surfactant by 30 minutes of age. Even later, (before 6 hours of age) still 29% had been given surfactant [9]. In the group of infants with gestational age less than 27 weeks, only 32% received surfactant in the delivery room. The European consensus guidelines now recommend a prophylactic surfactant

TABLE 1: Patients' characteristics.

	Prophylactic surfactant group (observational period) <i>n</i> = 31	Selective surfactant group (historical control) <i>n</i> = 34	Significance
Birthweight (g)	709 ± 164	701 ± 159	n.s.
Gestational age (wks+d)	25 + 1 (23 + 1 to 26 + 6)	25 + 3 (23 + 1 to 26 + 5)	n.s.
Male sex (%)	54	41	n.s.
Antenatal steroids (%)	90	91	n.s.
APGAR-Score (5 minutes)	7	7	n.s.
SGA (%)	29	15	n.s.
Multiple births (%)	7	9	n.s.
GA < 24 wks (%)	19	18	n.s.

SGA:small for gestational age (birth weights below 10th percentile); GA:gestational age; wks, weeks; d, days.

TABLE 2: Mortality and morbidity.

	Prophylactic surfactant group (observational period) <i>n</i> = 31	selective surfactant group (historical control) <i>n</i> = 34	Significance
Death until term	5 (16%)	6 (18%)	n.s.
IVH> II	4 (13%)	3 (9%)	n.s.
PVL	3 (10%)	1 (3%)	n.s.
Pneumothorax	1 (3%)	4 (9%)	n.s.
CLD	8 (26%)	13 (38%)	n.s.
PIE	0 (0%)	3 (9%)	n.s.
Need for mechanical ventilation (h per patient)	74 ± 26	171 ± 35	<i>P</i> = .03
Diagnosis of PDA	22 (71%)	28 (82%)	n.s.
Treatment of PDA	21 (68%)	26 (68%)	n.s.
NEC	1 (3%)	5 (15%)	n.s.
Nosocomial infection	14 (45%)	15 (44%)	n.s.
Postnatal steroids	19 (61%)	21 (62%)	n.s.
Surfactant doses	41	62	n.s.
Surfactant doses per patient	1.3	1.8	n.s.

IVH:intraventricular hemorrhage; PVL:periventricular leukomalacia; CLD:chronic lung disease (need of additional oxygen after 36 weeks gestational age); PIE:pulmonary interstitial emphysema; PDA:patent ductus arteriosus; NEC:necrotizing enterocolitis (stadium II or III according to Bell).

therapy within 15 minutes of birth to almost all babies under 27 weeks' gestation [10]. In our study, we address the question whether this strategy improves respiratory outcome in very premature infants under 27 weeks' gestation.

According to other studies [1, 7], we found a reduced incidence of pulmonary interstitial emphysema and pneumothoraces, although those variables did not reach significance. The risk of developing chronic lung disease after prophylactic surfactant compared with rescue surfactant has been discussed and remains controversial. Secondary analyses of clinical trials reported no different [1], decreased [11–13], and increased [14] risk of CLD in preterm infants who received prophylactic surfactant compared with those who received later selective surfactant treatment. Reininger et al. [15] compared the effect of one dose of intratracheally administered surfactant followed by extubation to nasal CPAP with nasal CPAP alone in infants 29 to 35 weeks' gestation with mild-to-moderate RDS requiring supplemental oxygen and NCPAP. 57% of the infants in the control group and 46% of the infants in the surfactant group received antenatal steroids. Reininger et al. showed a significantly

decreased need for mechanical ventilation with the use of prophylactic surfactant administration and identified a trend toward a decrease in the incidence of bronchopulmonary dysplasia (BPD).

In line with these studies, we also observed a trend to a decreased incidence of chronic lung disease. Nevertheless, the significant shortening of the time of mechanical ventilation turned out to be the most dramatic result of our study. This in turn could contribute to reduce the risk for mechanical ventilation associated complications.

Nasal CPAP is currently a first-line technique of respiratory support in newborns, and its use as an alternative to intubation and mechanical ventilation, also in extremely low gestational age infants, is well documented [3, 4]. Few randomized trials have compared different approaches of intubation with surfactant administration and mechanical ventilation versus early nasal CPAP. The results of these studies did not highlight significant differences [16–18]. Morley et al. [17] compared initial CPAP (8 cm H₂O) with initial intubation in the delivery room in infants 25 to 28 weeks of gestational age (COIN trial). They found a better

outcome at 28 days in the CPAP group compared to the intubation group; the two groups had a similar outcome at 36 weeks' gestational age. Early nasal CPAP did not significantly reduce the rate of death or bronchopulmonary dysplasia, as compared with intubation. The benefits of CPAP included a lower risk of combined outcome of death or the need for oxygen therapy at 28 days and fewer days of assisted ventilation. There is no information about the days of assisted ventilation in the CPAP subgroup of infants at 25 or 26 weeks' of gestation. In contrast, we found a significant decrease in the need for mechanical ventilation after intubation and prophylactic surfactant administration. In the COIN trial, sick infants who required immediate intubation were excluded and timing, dosing, and preparation of surfactant were not mandated and followed local protocols. The death rate at day 28 in the CPAP subgroup of infants at 25 or 26 weeks' of gestation was more than twice as high as in the intubation group (odds ratio 2.04; 95% CI 0.72–5.74), but this failed to meet statistical significance.

Verder et al. [19, 20] showed a low mortality and low morbidity when INSURE method (intubation-surfactant treatment-extubation) was used for treatment of very premature infants with RDS. Taken together, there is increasing evidence suggesting intubation and prophylactic administration of surfactant in extremely premature infants.

There are many pathophysiologic reasons why prophylactic surfactant therapy might be more effective and lead to less lung injury than late surfactant therapy for established RDS. In a surfactant-deficient lung of an air-breathing animal, there is ongoing leakage of serum proteins into alveolar space. These proteins act as inhibitors of surfactant function [21]. Jobe et al. [22] and Ikegami et al. [23] have demonstrated that early exogenous surfactant administration can reduce the protein leak, and others have shown that early administration of surfactant can lower severe lung injuries in RDS [24, 25].

6. Conclusion

From our data we conclude that infants under 27 weeks' gestation are "at risk" in developing RDS and profit from prophylactic surfactant administration by reducing the time of mechanical ventilation. This in turn could contribute to reduce the risk for mechanical ventilation associated complications (interstitial emphysema, pneumothoraces, and chronic lung disease) without any detrimental short-term side effects. As shown in the COIN trial [17], initial nasal CPAP did not significantly reduce the rate of death or bronchopulmonary dysplasia, as compared with initial intubation, but could increase the mortality rate in extremely preterm infants. Therefore, we consider that it is safer to intubate the smallest babies and administer prophylactic surfactant.

Due to the retrospective nature and the small sample size of our clinical trial more prospective, randomized and controlled trials (like the forthcoming report on the NICHD Neonatal Research Network SUPPORT trial [26] and the CURPAP study [27]) are needed to test whether prophylactic

surfactant administration in very preterm infants is superior over the selective procedure.

References

- [1] R. F. Soll and C. J. Morley, "Prophylactic versus selective use of surfactant in preventing morbidity and mortality in preterm infants," *Cochrane Database of Systematic Reviews*, no. 2, Article ID CD000510, 2001.
- [2] H. L. Halliday, "Recent clinical trials of surfactant treatment for neonates," *Biology of the Neonate*, vol. 89, no. 4, pp. 323–329, 2006.
- [3] A. Ammari, M. Suri, V. Milisavljevic, et al., "Variables associated with the early failure of nasal CPAP in very low birth weight infants," *Journal of Pediatrics*, vol. 147, no. 3, pp. 341–347, 2005.
- [4] N. N. Finer, W. A. Carlo, S. Duara, et al., "Delivery room continuous positive airway pressure/positive end-expiratory pressure in extremely low birth weight infants: a feasibility trial," *Pediatrics*, vol. 114, no. 3, pp. 651–657, 2004.
- [5] M. Sperandio, B. Beedgen, R. Feneberg, et al., "Effectiveness and side effects of an escalating, stepwise approach to indomethacin treatment for symptomatic patent ductus arteriosus in premature infants below 33 weeks of gestation," *Pediatrics*, vol. 116, no. 6, pp. 1361–1366, 2005.
- [6] P. Gastmeier, C. Geffers, F. Schwab, J. Fitzner, M. Obladen, and H. Ruden, "Development of a surveillance system for nosocomial infections: the component for neonatal intensive care units in Germany," *Journal of Hospital Infection*, vol. 57, no. 2, pp. 126–131, 2004.
- [7] T. P. Stevens, E. W. Harrington, M. Blennow, and R. F. Soll, "Early surfactant administration with brief ventilation vs. selective surfactant and continued mechanical ventilation for preterm infants with or at risk for respiratory distress syndrome," *Cochrane Database of Systematic Reviews*, no. 4, Article ID CD003063, 2007.
- [8] R. Ramanathan, "Optimal ventilatory strategies and surfactant to protect the preterm lungs," *Neonatology*, vol. 93, no. 4, pp. 302–308, 2008.
- [9] J. D. Horbar, J. H. Carpenter, J. Buzas, et al., "Timing of initial surfactant treatment for infants 23 to 29 weeks' gestation: is routine practice evidence based?" *Pediatrics*, vol. 113, no. 6, pp. 1593–1602, 2004.
- [10] D. Sweet, G. Bevilacqua, V. Carnielli, et al., "European consensus guidelines on the management of neonatal respiratory distress syndrome," *Journal of Perinatal Medicine*, vol. 35, no. 3, pp. 175–186, 2007.
- [11] J. W. Kendig, R. H. Notter, D. C. Cox, et al., "A comparison of surfactant as immediate prophylaxis and as rescue therapy in newborns of less than 30 weeks' gestation," *New England Journal of Medicine*, vol. 324, no. 13, pp. 865–871, 1991.
- [12] J. Egberts, R. Brand, H. Walti, G. Bevilacqua, G. Bréart, and F. Gardini, "Mortality, severe respiratory distress syndrome, and chronic lung disease of the newborn are reduced more after prophylactic than after therapeutic administration of the surfactant Curosurf," *Pediatrics*, vol. 100, no. 1, p. E4, 1997.
- [13] G. Bevilacqua, S. Parmigiani, B. Robertson, et al., "Prophylaxis of respiratory distress syndrome by treatment with modified porcine surfactant at birth: a multicentre prospective randomized trial," *Journal of Perinatal Medicine*, vol. 24, no. 6, pp. 609–620, 1996.
- [14] M. J. Kresch and J. M. Clive, "Meta-analyses of surfactant replacement therapy of infants with birth weights less than

- 2000 grams,” *Journal of Perinatology*, vol. 18, no. 4, pp. 276–283, 1998.
- [15] A. Reininger, R. Khalak, J. W. Kendig, et al., “Surfactant administration by transient intubation in infants 29 to 35 weeks’ gestation with respiratory distress syndrome decreases the likelihood of later mechanical ventilation: a randomized controlled trial,” *Journal of Perinatology*, vol. 25, no. 11, pp. 703–708, 2005.
 - [16] M. A. Thomson, “Continuous positive airway pressure and surfactant; combined data from animal experiments and clinical trials,” *Biology of the Neonate*, vol. 81, supplement 1, pp. 16–19, 2002.
 - [17] C. J. Morley, P. G. Davis, L. W. Doyle, L. P. Brion, J.-M. Hascoet, and J. B. Carlin, “Nasal CPAP or intubation at birth for very preterm infants,” *New England Journal of Medicine*, vol. 358, no. 7, pp. 700–708, 2008.
 - [18] F. Sandri, G. Ancora, A. Lanzoni, et al., “Prophylactic nasal continuous positive airways pressure in newborn of 28–31 weeks gestation: multicentre randomised controlled clinical trial,” *Archives of Disease in Childhood*, vol. 89, no. 5, pp. F394–F398, 2004.
 - [19] H. Verder, P. Albertsen, F. Ebbesen, et al., “Nasal continuous positive airway pressure and early surfactant therapy for respiratory distress syndrome in newborns of less than 30 weeks’ gestation,” *Pediatrics*, vol. 103, no. 2, p. E24, 1999.
 - [20] H. Verder, B. Robertson, G. Greisen, et al., “Surfactant therapy and nasal continuous positive airway pressure for newborns with respiratory distress syndrome. Danish-Swedish Multicenter Study Group,” *New England Journal of Medicine*, vol. 331, no. 16, pp. 1051–1055, 1994.
 - [21] M. Ikegami, H. Jacobs, and A. Jobe, “Surfactant function in respiratory distress syndrome,” *Journal of Pediatrics*, vol. 102, no. 3, pp. 443–447, 1983.
 - [22] A. Jobe, M. Ikegami, H. Jacobs, S. Jones, and D. Conaway, “Permeability of premature lamb lungs to protein and the effect of surfactant on that permeability,” *Journal of Applied Physiology*, vol. 55, no. 1, pp. 169–176, 1983.
 - [23] M. Ikegami, A. H. Jobe, S. Seidner, and T. Yamada, “Gestational effects of corticosteroids and surfactant in ventilated rabbits,” *Pediatric Research*, vol. 25, no. 1, pp. 32–37, 1989.
 - [24] G. Grossmann, R. Nilsson, and B. Robertson, “Scanning electron microscopy of epithelial lesions induced by artificial ventilation of the immature neonatal lung: the prophylactic effect of surfactant replacement,” *European Journal of Pediatrics*, vol. 145, no. 5, pp. 361–367, 1986.
 - [25] T. A. Merritt, M. Hallman, K. Holcomb, et al., “Human surfactant treatment of severe respiratory distress syndrome: pulmonary effluent indicators of lung inflammation,” *Journal of Pediatrics*, vol. 108, no. 5 I, pp. 741–748, 1986.
 - [26] “Surfactant positive airway pressure and pulse oximetry trial (SUPPORT),” <http://clinicaltrials.gov/ct2/show/NCT00233324>.
 - [27] F. Sandri, R. Plavka, and U. Simeoni, “The CURPAP study: an international randomized controlled trial to evaluate the efficacy of combining prophylactic surfactant and early nasal continuous positive airway pressure in very preterm infants,” *Neonatology*, vol. 94, no. 1, pp. 60–62, 2008.